Skip to main content
Oncodesign Precision Medicine S.A logo

Oncodesign Precision Medicine S.A — Investor Relations & Filings

Ticker · ALOPM ISIN · FR001400CM63 LEI · 969500ZDX1IY47LDL876 Euronext Access Plus Manufacturing
Open in API
Filings indexed 86 across all filing types
Latest filing 2026-04-30 Regulatory Filings
Country FR France
Listing Euronext Access Plus ALOPM

About Oncodesign Precision Medicine S.A

https://www.oncodesign.com/

Oncodesign Precision Medicine (OPM) is a biopharmaceutical company specializing in precision medicine. The company's mission is to develop and provide innovative therapeutic and diagnostic solutions to address therapeutic resistance and metastasis in cancer. OPM focuses on creating value through a patient-centric and translational approach, collaborating with clinicians, service providers, and experts. Its core activities are centered on discovering new treatments for resistant and metastatic cancers, aiming to identify the most effective therapeutic pathways for patients.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Communiqué sur comptes, résultats
Regulatory Filings
2026-04-30 French
Inside Information / News release on accounts, results
Regulatory Filings
2026-04-30 English
Inside Information / Other news releases
Capital/Financing Update Classification · 1% confidence The document is a press release from Oncodesign Precision Medicine (OPM) announcing that they have been awarded a $6.92 million grant from The Michael J. Fox Foundation to advance the development of their LRRK2 inhibitor, OPM-201. This is a corporate announcement regarding financing/capital support for a specific R&D project. It does not fit into periodic financial reporting (10-K, IR), management changes (MANG), or shareholder voting (DVA). It is best classified as a Capital/Financing Update (CAP) as it details the receipt of significant external funding for clinical development.
2026-03-03 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release from Oncodesign Precision Medicine (OPM) announcing the receipt of a research grant from the Michael J. Fox Foundation for Parkinson's research. It details the funding amount, the purpose of the grant (advancing the OPM-201 inhibitor), and provides background on the company's pipeline and technology. This is a corporate announcement regarding business development and financing, which falls under the 'Regulatory Filings' (RNS) category as it is a general corporate announcement that does not fit into more specific categories like earnings releases, annual reports, or M&A activity.
2026-03-03 French
Acquisition ou cession des actions de l'émetteur / Information relative au contrat de liquidité
Transaction in Own Shares Classification · 1% confidence The document is a 'Bilan semestriel du contrat de liquidité' (Semi-annual liquidity contract report) for Oncodesign Precision Medicine. This type of filing details the transactions made by a liquidity provider (TP ICAP) on behalf of the company to maintain share liquidity. According to the provided definitions, reports detailing the company buying back or selling its own shares (or liquidity contract activity) are classified as 'Transaction in Own Shares' (POS).
2026-01-21 French
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document is a press release announcing a new research collaboration between Oncodesign Precision Medicine (OPM) and Ksilink. It details the nature of the partnership, the technology involved (Nanocyclix), and the strategic goals for both companies. It does not fit into financial reporting categories like 10-K, IR, or ER, nor is it a regulatory filing or a specific corporate action like a dividend or share issue. As it is a general corporate announcement regarding business development and partnerships, it falls under the 'Regulatory Filings' (RNS) category as the appropriate fallback for miscellaneous corporate news.
2026-01-08 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.